Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the antitumor activity and potential adverse effects of
the combination celecoxib plus carboplatin in patients with recurrent, heavily pre-treated
Ovarian Cancer (OC). The potential changes induced by the experimental combination on
angiogenesis-related serum markers and quality of life measures will be also evaluated.The
main objective is to evaluate the response rate. Secondary objectives are the
following:toxicity;progression free survival;overall survival;duration of response;quality of
life;modulation of angiogenesis-related molecules.